Today we provide further evidence that people with Progressive MS can respond to DMT
MS is neurodegenerative from day one to the last day and is also inflammatory from day one to the last day.
Why don't we do something about the inflammation in MS in every one?.
The simple answer is due to cost-effectiveness.
The powers that be have decided that it is not cost-effective to use high cost treatments in people with progressive/Advanced MS.
Will this change with the demonstration that orelizumab is useful in PPMS.
We have been using generic cladribine, which is a potent DMT at a fraction of the cost of other MS drugs.
Disease activity can be seen on MRI scans.
In this study we have used neurofilaments, as a biomarker of ongoing nerve damage, to help inform on people who may respond to DMT treatment. People treated have shown a marked decrease in neurofilament loss, so the treatment is blocking the processes that lead to nerve damage.
Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine
Want to read the full paper?
It is free for fifty days (CLICK HERE)
Your personalized Share Link:
CoI This is work by DrK and other members of the Team